AuDHDeepDive
A
This is an EXTREMELY important lawsuit about how pharma companies withhold better treatments from market to maximize patent profits of existing, inferior drugs.
It’s about AIDS, but the same is happening with COVID vaccines and other drugs.
09:49 AM - Jul 23, 2023
Avatar Avatar Avatar
0
7
5
AuDHDeepDive
A
In response to AuDHDeepDive.
The promising drug, then in the early stages of testing, was an updated version of tenofovir. Executives knew it had the potential to be less toxic to patients’ kidneys and bones than the earlier iteration, according to internal memos unearthed by lawyers who are suing Gilead on behalf of patients.
09:49 AM - Jul 23, 2023
1
0
AuDHDeepDive
A
Despite those possible benefits executives concluded that the new version risked competing with the company’s existing, patent-protected formulation. If they delayed the new product release until shortly before the existing patents expired, the company could substantially increase the period of time
In response to AuDHDeepDive.
09:50 AM - Jul 23, 2023
1
0
AuDHDeepDive
A
In response to AuDHDeepDive.
in which at least one of its H.I.V. treatments remained protected by patents. The “patent extension strategy,” as the Gilead documents repeatedly called it, would allow the company to keep prices high for its tenofovir-based drugs.
09:51 AM - Jul 23, 2023
1
0
AuDHDeepDive
A
In response to AuDHDeepDive.
Gilead could switch patients to its new drug just before cheap generics hit the market. By putting tenofovir on a path to remain a moneymaking juggernaut for decades, the strategy was potentially worth billions of dollars.
09:51 AM - Jul 23, 2023
1
0

 

{{ notificationModalContent }} {{ promptModalMessage }}